REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: targeted pill shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2 or SWI/SNF) in their tumors. The goal was to see if the drug could shrink or control the cancer. This is a dise…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug combo shows promise for tough lymphomas
Disease control CompletedThis early-phase trial tested the safety and best dose of olaparib combined with high-dose chemotherapy in 50 adults with lymphomas that returned or didn't respond to treatment. Participants received the drug combo before a stem cell transplant. The goal was to see if adding olap…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 07, 2026 18:38 UTC
-
New drug combo may reduce transplant complications in blood cancer patients
Disease control CompletedThis study tested different combinations of immune-suppressing drugs to prevent graft-versus-host disease (GVHD) in 174 patients with blood cancers who received a stem cell transplant from an unrelated donor. The goal was to find the most effective approach to reduce severe GVHD,…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New drug flotetuzumab tested for tough blood cancers
Disease control CompletedThis early-stage trial tested the safety and best dose of flotetuzumab, a lab-made antibody, in 13 people with advanced blood cancers that had come back or stopped responding to treatment. The goal was to see if the drug could help control the disease by blocking cancer cell grow…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
Promising combo for Tough-to-Treat hodgkin lymphoma shows progress
Disease control CompletedThis study tested a new combination of a targeted drug (brentuximab vedotin) with standard chemotherapy for people whose Hodgkin lymphoma returned or didn't respond to treatment. The goal was to find the safest dose and see how many patients achieved complete remission. 45 adults…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC